| capecitabine / Generic mfg. |
NCT00040859: Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer |
|
|
| Completed | 2 | 48 | US | capecitabine, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 01/05 | 04/08 | | |
NCT00054457: Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction |
|
|
| Completed | 2 | 46 | US | capecitabine, docetaxel | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 02/07 | 02/08 | | |
| Completed | 2 | 72 | Europe | Matuzumab, EMD 72000, Epirubicin, Cisplatin, Capecitabine | Merck KGaA, Darmstadt, Germany | Esophageal Cancer, Gastric Cancer | 07/08 | 08/08 | | |
NCT00084617: Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma |
|
|
| Completed | 2 | 39 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, capecitabine, CAPE, Ro 09-1978/000, Xeloda | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer | 10/08 | 12/08 | | |
NCT00711412: Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 44 | US | Induction Therapy - Capecitabine, Induction Therapy - Oxaliplatin, Combination Therapy - Capecitabine, Combination Therapy - Oxaliplatin, Combination Therapy - Radiation, Evaluation for response and surgery | Northwestern University | Esophageal Cancer | 05/09 | 01/13 | | |
NCT00220129: Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus |
|
|
| Completed | 2 | 16 | Europe | Epirubicin, Cisplatin, Capecitabine, Surgical Resection | Royal Marsden NHS Foundation Trust | Oesophageal Carcinoma | | | | |
NCT00220103: Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma |
|
|
| Completed | 2 | 80 | Europe | epirubicin, capecitabine, cisplatin, Surgical resection | Royal Marsden NHS Foundation Trust | Adenocarcinoma of Oesophagus | | | | |
NCT00583674 / 2007-003573-50: Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma |
|
|
| Completed | 2 | 171 | US, Europe, RoW | AMG 386 placebo, AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin, Capecitabine | Amgen | Gastrointestinal Cancer | 03/10 | 06/12 | | |
NCT00848783: Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers |
|
|
| Terminated | 2 | 8 | US | Irinotecan, CPT-11, Cisplatin, Surgery, Floxuridine, FUDR, Capecitabine, Xeloda | NYU Langone Health | Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer | 08/11 | 09/12 | | |
NCT00470184: Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer |
|
|
| Completed | 2 | 41 | US | capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy | Roswell Park Cancer Institute, National Comprehensive Cancer Network | Esophageal Cancer | 10/12 | | | |
NCT01710592 / 2006-003332-29: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer |
|
|
| Completed | 2 | 35 | Europe | Epirubicin, Oxaliplatin, Capecitabine, Docetaxel | Cancer Trials Ireland | Gastro Oesophageal Cancer | 12/12 | | | |
NCT00891878: Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Completed | 2 | 12 | US | capecitabine, sunitinib malate | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | 01/13 | 01/13 | | |
| Terminated | 2 | 76 | Europe | Lapatinib, Tyverb, Lapatinib plus capecitabine, Tyverb, Xeloda | National Center for Tumor Diseases, Heidelberg | GastroEsophageal Cancer | 02/13 | 10/13 | | |
|
NCT01123473 / 2009-011580-36: Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer |
|
|
| Terminated | 2 | 29 | Europe | capecitabine, cisplatin, epirubicin hydrochloride, fluorouracil, lapatinib ditosylate | European Organisation for Research and Treatment of Cancer - EORTC | Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer | 08/13 | 09/14 | | |
|
NCT01474642: Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Completed | 2 | 64 | RoW | Capecitabine/Cisplatin(XP), Capecitabine/Paditaxel(XG) | Samsung Medical Center | Advanced or Recurrent Esophageal Squamous Cell Carcinoma | 09/13 | 05/14 | | |
NCT00938470: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction |
|
|
| Completed | 2 | 73 | US | capecitabine, docetaxel, fluorouracil, oxaliplatin, radiation therapy, therapeutic conventional surgery | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer | 12/13 | 03/18 | | |
| Completed | 2 | 60 | US | capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) | Duke University, Hoffmann-La Roche, Sanofi, Genentech, Inc. | Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis | 01/14 | 07/14 | | |
|
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma |
|
|
| Completed | 2 | 22 | US | epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery. | Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University | Esophageal Cancer, Gastric Cancer | 02/15 | 02/15 | | |
|
| Terminated | 2 | 21 | Europe | Omegaven, Omega-3 fish oil | University Hospitals, Leicester | Esophageal Neoplasm, Gastric Neoplasm | 12/15 | 12/15 | | |
| Terminated | 2 | 20 | Europe | S-1, Teysuno, tegafur/gimeracil/oteracil, Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Heikki Joensuu | Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer, Rectum Cancer | 08/18 | 08/18 | | |
| Completed | 1b/2 | 130 | US, Canada, Europe, RoW | Capecitabine, Xeloda, Epirubicin, AMG 102, Cisplatin, Placebo | Amgen | Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer | 11/10 | 06/13 | | |
|
|
|
|
NCT00021047: Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor |
|
|
| Completed | 1/2 | | US | capecitabine, carboplatin, epirubicin hydrochloride | National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI) | Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific | | 06/04 | | |
NCT00130936: Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates |
|
|
| Terminated | 1/2 | 50 | Canada | Epirubicin, Carboplatin, Capecitabine | AHS Cancer Control Alberta | Gastric Cancer, Esophageal Cancer, Tumors | | 11/07 | | |
EOXP, NCT00667420: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma |
|
|
| Terminated | 1/2 | 17 | US | panitumumab, epirubicin, oxaliplatin, xeloda | Massachusetts General Hospital | Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 06/11 | 06/14 | | |
POXX, NCT00578071: Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer |
|
|
| Completed | 1/2 | 29 | US | Panitumumab, Capecitabine, Xeloda, Oxaliplatin, Radiation Therapy (RT) | Brian Czito, Amgen | Cancer of the Esophagus | 07/11 | 06/12 | | |
ACTION, NCT02273713: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma |
|
|
| Completed | 1/2 | 154 | Europe | Nab-paclitaxel, Abraxane | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celgene Corporation | Esophageal Cancer, Toxicity | 03/17 | 03/17 | | |
NCT01490749: Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer |
|
|
| Completed | 1/2 | 17 | US | RAD001, Everolimus, XELOX, Oxaliplatin and capecitabine, Eloxatin and Xeloda, Carboplatin, Paraplatin, Radiation | Emory University, Novartis | Esophageal Cancer, Neoplasms, Esophageal | 02/19 | 02/19 | | |
